Exudative Age‑Related Macular Degeneration - Symptoms, Causes, Treatment & Prevention

Overview

Exudative age‑related macular degeneration (AMD), also called wet AMD, is the advanced form of macular degeneration in which abnormal blood vessels grow beneath the macula and leak fluid or blood. The macula—located in the central portion of the retina—is responsible for sharp, detailed vision needed for reading, recognizing faces, and driving. When fluid accumulates or scar tissue forms, central vision deteriorates rapidly.

Exudative AMD accounts for only about 10–15% of all AMD cases, but it is responsible for roughly 80% of AMD‑related severe vision loss.¹ The condition predominantly affects people aged 60 years and older, with prevalence rising sharply after age 70.

Key statistics (2023‑2024 data):

• ≈ 12 million adults worldwide have some form of AMD; about 1.6 million have the exudative type.²
• In the United States, ≈ 1.8 million individuals live with wet AMD, representing ~0.5 % of the population.³
• Incidence is 2–3 times higher in people with a family history of AMD.

Symptoms

Symptoms can appear suddenly or develop over weeks. Early detection is crucial because treatment is most effective before permanent scarring occurs.

• Blurry or distorted central vision – straight lines may appear wavy (“metamorphopsia”).
• Dark or empty spot in the center of vision – often described as a “hole” or “blind spot.”
• Poor color perception – colors may look washed out.
• Difficulty reading or recognizing faces – especially in low‑light conditions.
• Need for brighter light when performing close‑up tasks.
• Rapid change – symptoms usually progress over days to weeks, unlike the slow decline of dry AMD.

Causes and Risk Factors

Pathophysiology

In wet AMD, a process called choroidal neovascularization (CNV) occurs. Underlying genetic and environmental factors trigger the release of vascular endothelial growth factor (VEGF), stimulating new, fragile blood vessels to grow from the choroid (the vascular layer beneath the retina) into the sub‑retinal space. These vessels leak fluid, blood, and lipids, disrupting the photoreceptor cells of the macula.

Major risk factors

• Age – risk rises sharply after 65 years.
• Genetics – polymorphisms in the CFH, ARMS2, and HTRA1 genes increase susceptibility.⁴
• Smoking – current smokers have a 2–3‑fold higher risk.⁵
• Race – higher prevalence in Caucasians; lower in African‑American and Asian populations.
• Obesity & high‑fat diet – associated with elevated inflammatory markers.
• Cardiovascular disease, hypertension, and hyperlipidemia – share pathophysiologic pathways with CNV.
• Excessive sunlight exposure without protective eyewear.
• History of dry AMD – most wet AMD cases evolve from an existing dry form.

Diagnosis

Diagnosis is clinical but relies heavily on imaging to confirm CNV and guide treatment.

Standard evaluation

• Comprehensive eye exam – visual acuity testing, dilated fundus examination.
• Amsler grid testing – patients look for distortions or missing areas in a grid pattern.

Imaging modalities

• Optical Coherence Tomography (OCT) – provides cross‑sectional retinal images, revealing fluid accumulation, sub‑retinal hemorrhage, or scar tissue.
• Fluorescein Angiography (FA) – dye injected intravenously highlights leaking vessels; gold standard for detecting CNV.
• Indocyanine Green Angiography (ICGA) – better visualizes deeper choroidal vessels, useful in atypical cases.
• Fundus Autofluorescence (FAF) – assesses retinal pigment epithelium health.

Blood tests are not required for diagnosis but may be ordered to evaluate systemic risk factors (lipid panel, blood pressure, HbA1c).

Treatment Options

Prompt therapy can preserve or improve vision in 30–40 % of patients, especially when started early.

Pharmacologic (Anti‑VEGF) Therapy

Anti‑VEGF agents inhibit the growth of abnormal vessels and reduce leakage.

• Ranibizumab (Lucentis) – FDA‑approved for wet AMD; typically 0.5 mg intravitreal injection monthly for 3 months, then as‑needed.
• Aflibercept (Eylea) – 2 mg injection; initial loading phase of 3 monthly doses, then every 8 weeks (or 4‑week interval if disease activity persists).
• Bevacizumab (Avastin) – off‑label, cost‑effective; 1.25 mg injection.
• Brolucizumab (Beovu) – newer agent with longer dosing intervals; monitor for intraocular inflammation.

Vision gains are usually observed within 1–2 months. Ongoing monitoring with OCT is essential to determine retreatment intervals.

Photodynamic Therapy (PDT)

Verteporfin (Visudyne) is activated by a low‑energy laser after intravenous infusion, selectively closing abnormal vessels. PDT is now rarely used as first‑line because anti‑VEGF agents are more effective, but it may be combined with anti‑VEGF in polypoidal choroidal vasculopathy.

Laser Photocoagulation

Direct thermal laser can seal leaking vessels if they are located outside the foveal center. Its use is limited due to collateral damage risk.

Surgical Options

• Sub‑macular surgery – removal of sub‑retinal blood or scar tissue; performed by a few specialist centers.
• Vitrectomy with tissue plasminogen activator (tPA) – used for large sub‑retinal hemorrhages.

Lifestyle & Adjunct Measures

• Nutrition – high‑dose AREDS2 formula (vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, copper 2 mg) can slow progression of dry AMD and may support outcomes after anti‑VEGF therapy.⁶
• Smoking cessation – reduces further vascular damage.
• Blood pressure and lipid control – manage systemic vascular health.

Living with Exudative Age‑Related Macular Degeneration

While treatment can halt disease activity, many patients experience permanent central vision loss. Adapting daily life is essential for safety and independence.

Vision‑rehabilitation strategies

• Amsler grid monitoring – perform at home daily; report new distortions promptly.
• Low‑vision aids – magnifiers, high‑contrast reading glasses, electronic video magnifiers, and smartphone apps (e.g., Magnifier, VoiceOver).
• Lighting – use bright, evenly distributed lighting; avoid glare by using matte filters.
• Contrast enhancement – high‑contrast (black‑on‑white) signage and tactile markers for cookware, medication bottles, and appliances.
• Orientation & mobility training – certified low‑vision specialists can teach techniques for safe navigation.

Emotional & psychosocial support

• Depression and anxiety are common; consider counseling, support groups, or online communities (e.g., Macular Disease Foundation).
• Family education improves adherence to treatment schedules and helps with transportation to appointments.

Follow‑up schedule

After the initial loading phase of anti‑VEGF injections, most ophthalmologists see patients every 4–8 weeks for OCT‑guided assessment. Missed appointments can allow fluid to re‑accumulate, leading to irreversible damage.

Prevention

Because genetic predisposition cannot be altered, prevention focuses on modifiable risk factors.

• Adopt a Mediterranean‑style diet rich in leafy greens, fatty fish, nuts, and olive oil.
• Maintain a healthy weight (BMI < 25 kg/m²).
• Exercise regularly – at least 150 minutes of moderate aerobic activity per week.
• Protect eyes from UV and blue light – wear sunglasses with 99‑% UV protection and consider blue‑light filtering lenses for screen use.
• Quit smoking – seek nicotine‑replacement therapy or counseling.
• Control systemic diseases – hypertension, diabetes, and hyperlipidemia should be treated per guidelines.
• Regular eye exams – adults ≥50 years should have a dilated retinal exam annually.
• Consider AREDS2 supplementation if you have intermediate dry AMD or a family history of wet AMD (consult your eye care provider).

Complications

If left untreated or if disease activity recurs, several serious complications may develop:

• Permanent central scotoma leading to legal blindness in the affected eye.
• Geographic atrophy – progressive loss of retinal pigment epithelium adjacent to scar tissue.
• Choroidal neovascular membrane fibrosis – irreversible scar that further degrades vision.
• Secondary retinal detachment – rare but vision‑threatening.
• Psychosocial impact – loss of independence, increased fall risk, depression.

When to Seek Emergency Care

---

**References**

1. Wong WL, et al. Global prevalence of age‑related macular degeneration and disease burden projection 2020‑2040. Lancet Glob Health. 2022.
2. International AMD Registry. Updated 2023. www.iamd.org
3. National Eye Institute, “Age‑Related Macular Degeneration Fact Sheet,” 2023.
4. Klein R, et al. Genetic susceptibility to AMD: CFH, ARMS2, HTRA1. Ophthalmology. 2021.
5. US Public Health Service. Smoking and AMD. CDC, 2022.
6. Age‑Related Eye Disease Study 2 Research Group. AREDS2 formulation and AMD progression. JAMA Ophthalmol. 2020.